Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | ddPCR for rapid screening of actionable KD mutations in CML

Hugues de Lavallade • 7 Dec 2019
ASH 2019
Chronic Myeloid Leukemia Leukemia

Hugues de Lavallade, MD, PhD, King’s College London, London, UK, outlines a novel droplet digital PCR-based (ddPCR) multiplex assay for rapid screening for a panel of BCR-ABL1 kinase domains mutations relevant for tyrosine kinase inhibitors (TKIs). Dr Lavallade discusses the pros and cons of the use of ddPCR in this setting, including the potential clinical benefits. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Hugues de Lavallade

1:37
NGS can detect low level KD mutations in CP-CML patients
Hugues de Lavallade • 7 Dec 2019
1:08
NGS for KD mutational analysis in CML patients on TKIs
Hugues de Lavallade • 7 Dec 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals